International Journal of Hepatology Research

**ISSN Print:** 2664-6595
**ISSN Online:** 2664-6609
IJHR 2023; 5(1): 21-23
www.hepatologyjournal.in
Received: 18-01-2023
Accepted: 19-02-2023

**Dr. Sarah Wagner**
Department of Medical Genomics, Heidelberg University, Heidelberg, Germany

**Dr. Elisa Schmidt**
Department of Medical Genomics, Heidelberg University, Heidelberg, Germany

**Corresponding Author:**
**Dr. Sarah Wagner**
Department of Medical Genomics, Heidelberg University, Heidelberg, Germany

# The role of next-generation sequencing in genetic screening of liver cancer

**Dr. Sarah Wagner and Dr. Elisa Schmidt**

**DOI:** https://doi.org/10.33545/26646595.2023.v5.i1a.20

**Abstract**
Liver cancer, primarily hepatocellular carcinoma (HCC), is one of the most lethal malignancies worldwide, often diagnosed at advanced stages. Early detection and personalized treatment strategies are essential for improving patient outcomes. Next-generation sequencing (NGS) has emerged as a transformative technology for genetic screening, enabling comprehensive analysis of the genetic landscape of liver cancer. This review explores the role of NGS in genetic screening for liver cancer, focusing on its applications in identifying genetic mutations, biomarkers for early detection, and therapeutic targets. We also discuss the challenges and future directions for implementing NGS in clinical practice for liver cancer management.

**Keywords:** Next-generation sequencing, hepatocellular carcinoma, liver cancer, genetic screening, biomarkers, precision medicine

## Introduction
Liver cancer is a significant global health burden, accounting for approximately 830,000 deaths annually. Hepatocellular carcinoma (HCC), the most common type of liver cancer, is associated with multiple risk factors, including chronic hepatitis B and C infections, alcohol consumption, non-alcoholic fatty liver disease (NAFLD), and cirrhosis. Despite advances in treatment, the prognosis for HCC remains poor, with a 5-year survival rate of less than 20%. Early diagnosis is critical to improving outcomes, but current screening methods, such as ultrasound and alpha-fetoprotein (AFP) testing, have limitations in sensitivity and specificity. Genetic alterations play a crucial role in the initiation and progression of liver cancer, with numerous mutations and genomic alterations identified in HCC tumors. Traditional genetic screening methods, such as Sanger sequencing, have been limited by their low throughput and inability to capture the complexity of the tumor genome. Next-generation sequencing (NGS) has revolutionized genetic screening by providing high-throughput, cost-effective, and comprehensive analysis of the entire genome or specific regions of interest. This review discusses the role of NGS in genetic screening for liver cancer, including its application in early detection, prognostic biomarkers, and personalized treatment approaches.

## Main Objective
The main objective of this paper is to explore the detection of neutrophil extracellular traps (NETs) in autoimmune diseases, examining their role in disease pathogenesis and progression.

## Next-Generation Sequencing: An Overview
Next-generation sequencing (NGS) represents a transformative technology in genomics, enabling rapid, large-scale sequencing of DNA and RNA. Unlike traditional Sanger sequencing, which is limited by its time-consuming and labor-intensive nature, NGS allows the simultaneous sequencing of millions of fragments, significantly enhancing throughput and lowering costs. This technological advancement has revolutionized genetic research, clinical diagnostics, and personalized medicine. At its core, NGS works by breaking down the genome into small fragments, sequencing each fragment individually, and then using bioinformatics tools to reassemble these fragments into a comprehensive sequence.

The most widely used NGS platforms, such as Illumina, Ion Torrent, and Pacific Biosciences, differ in their sequencing chemistry, read length, and error rates, but they all share the ability to sequence vast amounts of genetic material at an unprecedented speed. Illumina sequencing, for instance, is known for its high accuracy and has become the most commonly used platform for whole-genome and whole-exome sequencing. NGS has broad applications across various fields. In cancer research, it has enabled the identification of mutations, copy number variations, and other genomic alterations that drive tumor growth, leading to the development of targeted therapies. Studies have shown that NGS can detect rare somatic mutations in heterogeneous tumor samples, offering insights into tumor evolution and resistance mechanisms. For instance, NGS-based tests like Foundation One have been developed to profile tumours and identify actionable mutations for personalized cancer treatment. In infectious disease diagnostics, NGS has allowed for the rapid identification of pathogens by sequencing their genomes directly from clinical samples. This was especially evident during the COVID-19 pandemic, where NGS played a critical role in tracking the spread of SARS-CoV-2 variants. The ability to sequence viral genomes at scale has provided insights into viral evolution and the emergence of new variants, informing public health responses and vaccine development. Moreover, NGS has proven indispensable in genetic screening for inherited disorders. It enables whole-exome sequencing (WES) and whole-genome sequencing (WGS), which are used to detect genetic variants associated with rare diseases. Studies have demonstrated that WES can uncover previously undiagnosed conditions, improving diagnostic rates in patients with complex diseases of unknown origin. For example, NGS has been used to diagnose rare metabolic disorders by identifying mutations in key metabolic pathways. In prenatal screening, NGS-based non-invasive prenatal testing (NIPT) has become a widely accepted method for detecting chromosomal abnormalities, such as trisomy 21 (Down syndrome), by analyzing fetal DNA present in maternal blood. The sensitivity and specificity of NGS-based NIPT are significantly higher than traditional screening methods, reducing the need for invasive procedures like amniocentesis. The bioinformatics analysis of NGS data is an essential component of the workflow. Sequencing generates enormous amounts of data that must be processed, aligned to a reference genome, and interpreted. Tools like GATK, BWA, and SAM tools are commonly used for variant calling, alignment, and quality control. However, the analysis and interpretation of NGS data require specialized expertise, as the identification of clinically relevant variants among the vast number of detected variants can be challenging. Distinguishing between benign and pathogenic variants, particularly in the context of personalized medicine, is an ongoing challenge, necessitating comprehensive databases such as ClinVar and COSMIC for variant annotation. Despite its many advantages, NGS faces certain limitations. One significant challenge is the handling of large datasets, which require substantial computational power and storage capacity. Additionally, the accuracy of NGS can be affected by technical artifacts, such as GC bias and sequencing errors, although improvements in library preparation and sequencing chemistry have mitigated these issues. Another challenge is the interpretation of variants of uncertain significance (VUS), which can complicate clinical decision-making. NGS has also raised ethical concerns, particularly in the context of whole-genome sequencing. The ability to sequence an individual's entire genome raises questions about privacy, data ownership, and the potential misuse of genetic information. Moreover, incidental findings genetic information unrelated to the initial reason for testing present dilemmas about whether and how such information should be disclosed to patients. In conclusion, next-generation sequencing has revolutionized the fields of genomics, diagnostics, and personalized medicine, providing powerful tools for understanding the genetic underpinnings of diseases, tracking pathogen evolution, and tailoring treatments to individual patients. As the technology continues to evolve, with advances in long-read sequencing and single-cell sequencing, NGS is expected to further expand its applications and impact on science and healthcare. However, challenges related to data interpretation, cost, and ethical considerations must be addressed to fully realize the potential of this groundbreaking technology.

**Applications of NGS in genetic screening for liver cancer**

Next-generation sequencing (NGS) plays a pivotal role in the genetic screening of liver cancer, particularly hepatocellular carcinoma (HCC), enabling comprehensive analysis of the genetic mutations that drive cancer progression. By providing deep insights into the molecular underpinnings of liver cancer, NGS has transformed how clinicians and researchers approach the disease, from early detection to personalized treatment strategies. One of the most critical applications of NGS in liver cancer is in the early detection of genetic mutations that signal the onset of HCC. Traditional methods of diagnosing liver cancer, such as imaging and biomarker-based tests like alpha-fetoprotein (AFP), often detect the disease at a later stage. NGS, however, allows for the identification of mutations in circulating tumor DNA (ctDNA) from blood samples, offering a non-invasive method for detecting cancer at an earlier stage. Genetic alterations commonly seen in liver cancer, such as mutations in the TERT promoter, TP53, CTNNB1 (beta-catenin), and AXIN1, can be identified through NGS, allowing for earlier intervention. This is particularly important for high-risk populations, such as individuals with chronic hepatitis B or C infections or cirrhosis, where early detection can significantly improve prognosis.

NGS also facilitates the identification of the genetic landscape and tumor heterogeneity within liver cancer. Liver tumours are often genetically heterogeneous, with different regions of the tumor harboring distinct genetic mutations. Through NGS, researchers can sequence multiple regions of a single tumor to reveal this heterogeneity, providing a clearer picture of the tumour’s evolutionary pathways and identifying driver mutations that are critical for tumor growth. This detailed genetic information not only enhances our understanding of tumor biology but also informs the selection of targeted therapies, as certain mutations may render the tumor susceptible to specific treatments.

Moreover, NGS is instrumental in uncovering biomarkers that have prognostic and therapeutic significance. Genetic alterations detected by NGS can be linked to patient outcomes, providing prognostic insights. For example,

mutations in the TP53 gene are associated with poor prognosis, while CTNNB1 mutations are often linked to better outcomes. By using NGS to identify these biomarkers, clinicians can stratify patients based on their genetic profiles and tailor treatment plans accordingly. This approach is particularly valuable in the era of precision medicine, where treatments are increasingly being personalized based on the molecular characteristics of the patient's tumor. One of the most promising applications of NGS in liver cancer is in the realm of personalized treatment. Targeted therapies, which aim to disrupt specific molecular pathways involved in cancer progression, have become a key component of cancer treatment. NGS can identify actionable mutations in liver cancer patients, such as alterations in the PI3K/AKT/mTOR pathway, which can be targeted by specific inhibitors. Additionally, NGS can help identify patients who may benefit from immunotherapy, as certain genetic markers, such as high tumor mutational burden (TMB) or microsatellite instability (MSI), can predict responsiveness to immune checkpoint inhibitors. This ability to match patients with the most effective treatments based on their genetic profiles represents a major advancement in the treatment of liver cancer. Furthermore, NGS is valuable for monitoring treatment response and detecting resistance mechanisms. As patients undergo treatment, their tumors can evolve, potentially acquiring new mutations that confer resistance to therapy. NGS can be used to track these changes over time by analyzing serial biopsies or ctDNA from blood samples, allowing clinicians to adjust treatment strategies as needed. This dynamic monitoring of tumor evolution through NGS enhances the ability to manage liver cancer more effectively, particularly in patients with advanced or recurrent disease.

While the benefits of NGS in liver cancer are substantial, there are also challenges associated with its clinical implementation. The sheer volume of data generated by NGS requires sophisticated bioinformatics tools for analysis and interpretation, and distinguishing between driver mutations (those that promote cancer) and passenger mutations (those that are incidental) can be difficult. Additionally, the cost of NGS, though decreasing, remains a barrier to its widespread adoption in some healthcare settings. Despite these challenges, ongoing advancements in NGS technology and bioinformatics are expected to make genetic screening more accessible and streamlined in the near future.

## Future Directions

The future of NGS in liver cancer screening lies in the integration of multi-omics approaches, combining genomic, transcriptomic, and proteomic data to provide a more comprehensive understanding of liver cancer biology. Advances in single-cell sequencing may also allow for a more detailed analysis of tumor heterogeneity and the identification of rare cell populations that drive cancer progression.

Liquid biopsy, which involves analyzing ctDNA, circulating tumor cells (CTCs), and other biomarkers in blood samples, holds great promise for non-invasive cancer screening and monitoring. As NGS technologies continue to evolve, their sensitivity and specificity will improve, making them more suitable for early detection and real-time monitoring of liver cancer.

## Conclusion

Next-generation sequencing has revolutionized the field of genetic screening for liver cancer by enabling comprehensive analysis of the tumor genome. NGS has the potential to significantly improve the early detection, diagnosis, and treatment of liver cancer through the identification of genetic mutations and biomarkers. Despite challenges related to data interpretation, cost, and tumor heterogeneity, the integration of NGS into clinical practice holds great promise for the future of personalized medicine in liver cancer. Continued advancements in NGS technology and bioinformatics will further enhance its role in improving patient outcomes in liver cancer management.

## References

1. Marquardt JU, Andersen JB. Next-generation sequencing: application in liver cancer past, present and future?. Biology. 2012 Aug 31;1(2):383-394.
2. Li S, Mao M. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Cancer Letters. 2013 Nov 1;340(2):247-253.
3. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology. 2016 Nov 1;65(5):1031-1042.
4. Stephen NB, Madduru D, Pappu P, Vijay U, Suravajhala P, Bandapalli OR. Hepatocarcinogenesis and the role of next-generation sequencing in liver cancer. In: Theranostics and precision medicine for the management of hepatocellular carcinoma, Volume 2. Academic Press; c2022, p. 45-57.
5. Eso Y, Kou T, Nagai H, Kim YH, Kanai M, Matsumoto S, *et al*. Utility of ultrasound-guided liver tumor biopsy for next-generation sequencing-based clinical sequencing. Hepatology Research. 2019 May;49(5):579-589.
6. Mikhail S, Faltas B, Salem ME, Saab BT. Application of next-generation sequencing in gastrointestinal and liver tumors. Cancer leTters. 2016 May 1;374(2):187-191.
7. Chen M, Zhao H. Next-generation sequencing in liquid biopsy: Cancer screening and early detection. Human genomics. 2019 Aug 1;13(1):34.
8. Nicastro E, D'Antiga L. Next-generation sequencing in pediatric hepatology and liver transplantation. Liver transplantation. 2018 Feb;24(2):282-293.
9. Ahmed E, El-Dien AN, Sabet S, Khalifa M, El Hamshary M. Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing. Biomarkers. 2023 May 19;28(4):379-386.